Insulin detemir (DET) reduces glycemia comparably to other long-acting insulin formulations but causes less weight gain. Insulin signaling in the brain is catabolic, reducing food intake. We hypothesized that DET reduces weight gain, relative to other insulins, owing to increased transport into the central nervous system and/or increased catabolic action within the brain. Transport of DET and NPH insulin into the cerebrospinal fluid (CSF) was compared over several hours and after the administration of different doses peripherally in rats. DET and NPH had comparable saturable, receptor-mediated transport into the CSF. CSF insulin remained elevated significantly longer after intraperitoneal DET than after NPH. When administered acutely into the 3rd cerebral ventricle, both DET and NPH insulin reduced food intake and body weight at 24 h, and both food intake and body weight remained lower after DET than after NPH after 48 h. In direct comparison with another long-acting insulin, insulin glargine (GLAR), DET led to more prolonged increases in CSF insulin despite a shorter plasma half-life in both rats and mice. Additionally, peripheral DET administration reduced weight gain and increased CSF insulin compared with saline or GLAR in mice. Overall, these data support the hypothesis that DET has distinct effects on energy balance through enhanced and prolonged centrally mediated reduction of food intake.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4477354PMC
http://dx.doi.org/10.2337/db14-1364DOI Listing

Publication Analysis

Top Keywords

det nph
20
food intake
16
insulin
12
nph insulin
12
weight gain
12
csf insulin
12
det
10
insulin detemir
8
cerebrospinal fluid
8
insulin insulin
8

Similar Publications

Article Synopsis
  • - The study aimed to compare glycemic control and outcomes in women with gestational diabetes treated with either insulin detemir or insulin NPH.
  • - It included 192 women, with no significant differences in insulin dosage or maternal weight gain between the two treatment groups, but a slightly lower HbA1c was observed in the detemir group.
  • - Overall, insulin detemir was found to be equally effective and safe compared to NPH for managing gestational diabetes without causing hypoglycemia or allergic reactions.
View Article and Find Full Text PDF

Insulin detemir (DET) reduces glycemia comparably to other long-acting insulin formulations but causes less weight gain. Insulin signaling in the brain is catabolic, reducing food intake. We hypothesized that DET reduces weight gain, relative to other insulins, owing to increased transport into the central nervous system and/or increased catabolic action within the brain.

View Article and Find Full Text PDF

Background: We performed a comparative analysis of the use of long-acting insulin (analogues) neutral protamine hagedorn (NPH), detemir (Det) and glargine (Gla), and quantified injection frequencies and daily insulin doses in patients with type 1 and 2 diabetes in daily practice.

Methods: A total number of 51 964 patients from 336 centres in Germany and Austria with type 1 and 2 diabetes with exclusive insulin therapy were retrospectively analysed.

Results: A total number of 42.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!